187P Phase I/II study of the oral CCR4 antagonist, FLX475, as monotherapy and in combination with pembrolizumab in advanced cancer

C-C. Lin,T.M. Kim, P. Desai, K.H. Lee, Y-H. Feng, N. Ngamphaiboon,S-B. Kim,M-H. Yang, J. Muzaffar, B. Chmielowski,P.L. Swiecicki, S.E. Bowyer, J.R. Brahmer, M. Chisamore, R. Goyal, N. Nasrah, W. Ho, B.C. Cho

Immuno-Oncology and Technology（2022）

引用 0|浏览4

暂无评分

摘要

Preclinical studies with oral CCR4 antagonists have demonstrated inhibition of suppressive regulatory T cell (Treg) migration into the tumor microenvironment and antitumor efficacy. The FLX475-02 trial is a phase 1/2, open-label, dose-escalation and cohort expansion study to determine the safety and antitumor activity of the oral CCR4 antagonist FLX475 as monotherapy and in combination with pembrolizumab in subjects with several types of advanced cancer.

查看译文

关键词

oral ccr4 antagonist,pembrolizumab,monotherapy,advanced cancer,flx475

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要